Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.

Saved in:
Bibliographic Details
Title: Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.
Authors: Tellenbach FL; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Seiler L; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Johnson M; SpringWorks Therapeutics, Stamford, Connecticut, USA., Rehrauer H; Functional Genomics Center Zurich, University of Zurich, Zurich, Switzerland., Schukla P; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Martinez-Gomez J; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Stoffel CI; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Kamal A; SpringWorks Therapeutics, Stamford, Connecticut, USA., Dummer R; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Levesque MP; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Eichhoff OM; Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Source: Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2025 Nov; Vol. 38 (6), pp. e70062.
Publication Type: Journal Article
Journal Info: Publisher: Blackwell Munksgaard Country of Publication: England NLM ID: 101318927 Publication Model: Print Cited Medium: Internet ISSN: 1755-148X (Electronic) Linking ISSN: 17551471 NLM ISO Abbreviation: Pigment Cell Melanoma Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1755-148X
DOI:10.1111/pcmr.70062